Court Rules in Eurofins Viracor’s favor in Patent Infringement Case
01 Octobre 2021 - 7:15AM
Business Wire
Regulatory News:
The United States District
Court for District of Delaware has ruled that the patent asserted
in CareDx’s patent infringement case against Eurofins Viracor is
invalid. Eurofins Viracor is very pleased that the Court has agreed
with its arguments and issued judgment in Eurofins Viracor’s favor
in this challenge to Eurofins’ critically important diagnostic
tools to manage organ rejection risk.
Eurofins Viracor’s offerings
include Viracor TRAC® Kidney dd-cfDNA, Viracor TRAC® Heart dd-cfDNA
and Viracor TRAC® Lung dd-cfDNA. In related innovation for
transplant patients earlier this week, Eurofins Viracor’s
affiliate, Transplant Genomics, Inc. (“TGI”), launched OmniGraf™,
which combines the TruGraf® blood gene expression test and Viracor
TRAC® donor-derived cell-free DNA assays. For renal transplant
recipients, OmniGraf™ Kidney represents the first diagnostic tool
that combines cell free DNA and gene expression data. When combined
with TGI’s proprietary technology and machine learning, the test
offers patients and clinicians an early and accurate assessment of
kidney transplant rejection.
OmniGraf™ is a trademark of Transplant Genomics, Inc.
TruGraf® is a registered trademark of Transplant
Genomics, Inc.
Viracor TRAC® is a registered trademark of Eurofins
Viracor, LLC
Notes to Editors:
For more information, please visit
https://www.eurofins-viracor.com/clinical/
About Viracor
With over 30 years of specialised expertise in infectious
disease, immunology and allergy testing for immunocompromised and
critical patients, Viracor Eurofins is committed to delivering
results to medical professionals, transplant teams, reference
laboratories and biopharmaceutical companies faster, when it
matters most. Eurofins Viracor is passionate about delivering value
to its clients by providing timely, actionable information, never
losing sight of the connection between the testing it performs and
the patients it ultimately serves.
Eurofins Viracor is a subsidiary of Eurofins Scientific
(EUFI.PA), a global leader in bio-analytical testing, and one of
the world leaders in genomic services. For more information, please
visit https://www.eurofins.com/ and
https://www.eurofins-viracor.com/.
About Eurofins – the global leader in bio-analysis
Eurofins is Testing for Life. Eurofins is the global leader in
food, environment, pharmaceutical and cosmetic product testing and
in agroscience Contract Research Organisation services. Eurofins is
one of the market leaders in certain testing and laboratory
services for genomics, discovery pharmacology, forensics, advanced
material sciences and in the support of clinical studies, as well
as having an emerging global presence in Contract Development and
Manufacturing Organisations. The Group also has a rapidly
developing presence in highly specialised and molecular clinical
diagnostic testing and in-vitro diagnostic products.
With 55,000 staff across a decentralised and entrepreneurial
network of 900 laboratories in over 50 countries, Eurofins offers a
portfolio of over 200,000 analytical methods to evaluate the
safety, identity, composition, authenticity, origin, traceability
and purity of a wide range of products, as well as providing
innovative clinical diagnostic testing services and in-vitro
diagnostic products.
The Group’s objective is to provide its customers with
high-quality services, innovative solutions and accurate results on
time. Eurofins is ideally positioned to support its clients’
increasingly stringent quality and safety standards and the
increasing demands of regulatory authorities as well as the
requirements of healthcare practitioners around the world.
In 2020, Eurofins reacted quickly to meet the global challenge
of COVID-19, by creating the capacity to help over 20 million
patients monthly who may have been impacted by the pandemic with
our testing products and our services and directly supporting
healthcare professionals working on the front line to fight the
virus. The Group has established widespread PCR testing
capabilities and has carried out over 25 million tests in its own
laboratories, is supporting the development of a number of vaccines
and has established its SAFER@WORK™ testing, monitoring and
consulting programmes to help ensure safer environments, travel and
events during COVID-19.
Eurofins has grown very strongly since its inception and its
strategy is to continue expanding its technology portfolio and its
geographic reach. Through R&D and acquisitions, the Group draws
on the latest developments in the field of biotechnology and
analytical chemistry to offer its clients unique analytical
solutions.
Shares in Eurofins Scientific are listed on the Euronext Paris
Stock Exchange (ISIN FR0014000MR3, Reuters EUFI.PA, Bloomberg ERF
FP).
Until it has been lawfully made public widely by Eurofins
through approved distribution channels, this document contains
inside information for the purpose of Regulation (EU) 596/2014 of
the European Parliament and of the Council of 16 April 2014 on
market abuse, as amended.
Important disclaimer:
This press release contains forward-looking statements and
estimates that involve risks and uncertainties. The forward-looking
statements and estimates contained herein represent the judgment of
Eurofins Scientific’s management as of the date of this release.
These forward-looking statements are not guarantees for future
performance, and the forward-looking events discussed in this
release may not occur. Eurofins Scientific disclaims any intent or
obligation to update any of these forward-looking statements and
estimates. All statements and estimates are made based on the
information available to the Company’s management as of the date of
publication, but no guarantees can be made as to their completeness
or validity.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210930005999/en/
Sally Maysent Director of Marketing Email:
SallyMaysent@Eurofins-Viracor.com
Investor Relations Eurofins Scientific SE Phone: +32 2 766 1620
E-mail: ir@eurofins.com
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Eurofins Scientific (EU:ERF)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024